<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=412980&amp;fmt=gif">

OUR RESOURCES

FEATURED CONTENT

Investorview: Propelling life science innovation from pre-seed to patients

Denmark’s Novo Seeds was established in 2007 in order to identify promising scientific research in the Nordic region, build life sciences companies that deliver commercially-attractive opportunities to investors and pharma partners, and develop novel...

Read More

C-suite survey uncovers life sciences challenges

For more than three-quarters (78%) of C-level respondents in the life sciences sector, identifying relevant investors with an active investment mandate is one of the main hurdles to securing financing, according to the LSX C-Suite Challenges in Life ...

Read More

CASE STUDY

World-first accreditation to out-of-this-world applications for Oxehealth’s vital signs technology

Key learnings: Oxford-based Oxehealth has secured medical device accreditat...

Read More

Gates Foundation funding for DelSiTech’s silica-based drug delivery technology

Key learnings: DelSiTech has been awarded significant grant funding from th...

Read More

€79m Series C pushes Galecto Biotech’s pipeline into next phase of clinical development

Key learnings: Ysios Capital and OrbiMed led Galecto Biotech’s €79 million ...

Read More
View More

EXPERT INSIGHT

Medius Deal Watch: September-October 2018

There was much speculation last year that the US tax cuts that favoured the...

Read More

AI update: medical software and pre-emption

In light of the rapidly expanding field of medical software technology, and...

Read More
View More

INVESTORVIEW

Investorview: Propelling life science innovation from pre-seed to patients

Denmark’s Novo Seeds was established in 2007 in order to identify promising...

Read More

Investorview: Ingredients for growth in life sciences investment

Industrifonden is an evergreen venture capital fund with headquarters in St...

Read More

Investorview: Why people are key in life science investments

Since it was founded in 1996, European venture capital firm HealthCap has i...

Read More
View More

LSX REPORT

Have your say on life sciences investment trends

LSX, formerly Biotech and Money, is conducting the 3rd Investor Perception ...

Read More

Key challenges to scaling up early-stage investment in the life sciences

Access to venture capital and effective fundraising tactics are key to buil...

Read More

Brexit: finite uncertainty

One might think that planning for uncertainty is something that biotech fir...

Read More
View More

WHITE PAPER

Medius Deal Watch: September-October 2018

There was much speculation last year that the US tax cuts that favoured the...

Read More

Infographic: C-suite challenges in life sciences 2018

In early 2017, LSX, formerly Biotech and Money, published the inaugural Inv...

Read More

C-suite survey uncovers life sciences challenges

For more than three-quarters (78%) of C-level respondents in the life scien...

Read More
View More

VIDEO

Interview with Avacta Group's Alastair Smith

In this video, Donald Leggatt, Head of Investor Relations at London South E...

Read More

Interview with HemoGenyx's Vladislav Sandler

In this video, Donald Leggatt, Head of Investor Relations at London South E...

Read More

Interview with Inmedix’s Andrew J. Holman

Andrew J. Holman, Co-Founder and Chief Executive Officer at Inmedix, talks ...

Read More
View More

EVENT

Lifestars Awards 2018 celebrate life science successes

LSX (formerly Biotech and Money) hosted the Lifestars Awards at the Honoura...

Read More

Addressing emerging themes in life science IP

Marks & Clerk’s intellectual property (IP) summit in Cambridge on 16 Octobe...

Read More

Driving developments to defeat ageing: Q&A with Aubrey de Grey

In February 2019, key stakeholders in the growing longevity industry will c...

Read More
View More

WEBINAR

Advanced therapies: Gaining market access in a challenging European environment

Listen to the final session in Phacilitate and LSX's (formerly known as Bio...

Read More

Overcoming commercialisation challenges in advanced therapies

Learn more about the commercialisation of advanced therapies in the on-dema...

Read More

Why whistleblowing should be a boardroom issue in life sciences

On-demand webinar now available New EU-wide whistleblowing regulations have...

Read More
View More